Picture of Photocure ASA logo

PHO Photocure ASA Share Price

0.000.00%
no flag iconLast trade - 00:00
HealthcareSpeculativeSmall CapHigh Flyer

Momentum

Relative Strength (%)
1m-4.86%
3m-23.88%
6m-12.86%
1yr-4.73%
Volume Change (%)
10d/3m-57.39%
Price vs... (%)
52w High-23.78%
50d MA-3.94%
200d MA-0.31%

Growth & Value

12m Forecast RollingIndustryMarket
PE Ratio (f)97.66
PEG Ratio (f)n/a
EPS Growth (f)n/a
Dividend Yield (f)n/a
Valuation (ttm)IndustryMarket
Price to Book Value3.08
Price to Tang. Book6.58
Price to Free Cashflow41.26
Price to Sales2.97
EV to EBITDA22.09

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital4.39%
Return on Equity0.06%
Operating Margin5.55%

Financial Summary

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202431st Dec 2025
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2024 / 2025

Blurred out image of Photocure ASA EPS forecast chart

Profile Summary

Photocure ASA is a Norway-based company active in the pharmaceutical industry. The Company is focused on developing and improving photodynamic technology and owns a Photocure Technology platform, which develops photodynamic technology for diagnosis and therapy. Based on the Photocure Technology platform, Photocure has developed and commercialized Hexvix (Hyperthermic IntraVEsical Chemotherapy) and Cysview (hexaminolevulinate HCL) for use in bladder cancer. The Company’s activities are divided into two business segments: The Commercial Franchise and The Development Portfolio. The Commercial Franchise segment includes Hexvix/Cysview by geography (U.S. and Europe) and other sales (partners and other products including sales revenues for Hivec). The Development Portfolio segment includes development of pipeline products.

Directors

Last Annual
December 31st, 2023
Last Interim
December 31st, 2023
Incorporated
February 20th, 1995
Public Since
May 29th, 2000
No. of Employees
106
Sector
Pharmaceuticals
Industry
Healthcare
Exchange
no flag iconOslo Stock Exchange
Shares in Issue
27,105,698

PHO Share Price Performance

Upcoming Events for PHO

Q1 2024 Photocure ASA Earnings Release

Photocure ASA Annual Shareholders Meeting

Q2 2024 Photocure ASA Earnings Release

Similar to PHO

Picture of Arctic Bioscience AS logo

Arctic Bioscience AS

no flag iconOslo Stock Exchange

Picture of Navamedic ASA logo

Navamedic ASA

no flag iconOslo Stock Exchange

Picture of Vistin Pharma ASA logo

Vistin Pharma ASA

no flag iconOslo Stock Exchange

FAQ